Perrigo Confirms Settlement Of Generic Version Of Ofirmev Injection Patent Litigation
ALLEGAN — Allegan-based Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev (acetaminophen) injection brought by Cadence Pharmaceuticals Inc.
Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev (acetaminophen) injection on Dec. 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.
Ofirmev (acetaminophen) injection is administered intravenously as a single or repeated dose therapy for the reduction of fever and the treatment of mild to severe pain with or without adjunctive opioid analgesics. Ofirmev has annual sales of approximately $42 million, as measured by Wolters Kluwer.
“This settlement is another example of our long-term investment in extended product development,” aid Perrigo chairman, president and CEO Joseph C. Papa. “Perrigo continues its commitment to making quality healthcare more affordable for our customers.”
From its beginnings as a packager of generic home remedies in 1887, Perrigo has grown to become a leading global provider of over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients and is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market.
More at www.perrigo.com.